Evidence map›Paper›PMID 35523779›Full record

ArticleTranslational psychiatry2022

A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.

Liangsuo Ma, Kathryn A Cunningham, Noelle C Anastasio, James M Bjork, Brian A Taylor, Albert J Arias, Brien P Riley, Andrew D Snyder, F Gerard Moeller

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Liangsuo Ma *Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States. Liangsuo.ma@vcuhealth.org.ORCID 0000-0002-8856-098X
Kathryn A Cunningham *Center for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States. kcunning@utmb.edu.ORCID 0000-0002-4257-1739
Noelle C AnastasioCenter for Addiction Research and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States.ORCID 0000-0001-5579-4213
James M BjorkInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States.ORCID 0000-0003-0593-3291
Brian A TaylorInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States.
Albert J AriasInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States.
Brien P RileyVirginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, United States.ORCID 0000-0002-2408-8268
Andrew D SnyderInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States.
F Gerard MoellerInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, United States.
Virginia Commonwealth University · USThe University of Texas Medical Branch at Galveston · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Preclinical Assessment of Compounds for Cocaine Use Disorder (CocUD)U54DA038999 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2014 to 2018
$6.8M
Translational Addiction Sciences CenterP50DA033935 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2013 to 2017
$6.7M
NCATS NIH HHS UL1 TR002649NIDA NIH HHS P50 DA033935NIDA NIH HHS U54 DA038999
6 · The paper itself

Abstract

Cocaine use disorder (CUD) patients display heterogenous symptoms and unforeseeable responses to available treatment approaches, highlighting the need to identify objective, accessible biobehavioral signatures to predict clinical trial success in this population. In the present experiments, we employed a task-based behavioral and pharmacogenetic-fMRI approach to address this gap. Craving, an intense desire to take cocaine, can be evoked by exposure to cocaine-associated stimuli which can trigger relapse during attempted recovery. Attentional bias towards cocaine-associated words is linked to enhanced effective connectivity (EC) from the anterior cingulate cortex (ACC) to hippocampus in CUD participants, an observation which was replicated in a new cohort of participants in the present studies. Serotonin regulates attentional bias to cocaine and the serotonergic antagonist mirtazapine decreased activated EC associated with attentional bias, with greater effectiveness in those CUD participants carrying the wild-type 5-HT

Indexed as

CocaineCocaine-Related DisordersSubstance-Related DisordersGyrus CinguliHumansMirtazapineSerotoninCocaineMirtazapineSerotonin

Identifiers

PMID35523779
PMCPMC9076859
OpenAlexW4229071826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.